Literature DB >> 33382836

Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB.

Ditthawat Nonghanphithak1,2, Orawee Kaewprasert1,2, Pratchakan Chaiyachat1,2, Wipa Reechaipichitkul2,3, Angkana Chaiprasert4, Kiatichai Faksri1,2.   

Abstract

Drug resistance (DR) remains a major challenge for tuberculosis (TB) control. Whole-genome sequencing (WGS) provides the highest genetic resolution for genotypic drug-susceptibility tests (DST). We compared DST profiles of 60 Mycobacterium tuberculosis isolates which were drug resistant according to agar proportion tests (one poly DR-TB, 34 multidrug-resistant TB and 25 extensively drug-resistant TB). We additionally performed minimum inhibitory concentration (MIC) tests using Sensititre MYCOTBI plates (MYCOTB) and a WGS-based DST. Agreement between WGS-based DST and MYCOTB was high for all drugs except ethambutol (65%) and ethionamide (62%). Isolates harboring the -15 c/t inhA promoter mutation had a significantly lower MIC for isoniazid than did isolates with the katG Ser315Thr mutation (p < 0.001). Similar patterns were seen for ethambutol (embB Gly406Asp vs. embB Met306Ile), streptomycin (gid Gly73Ala vs. rpsL Lys43Arg), moxifloxacin (gyrA Ala90Val vs. gyrA Asp94Gly) and rifabutin (rpoB Asp435Phe/Tyr/Val vs. rpoB Ser450Leu). For genotypic heteroresistance, isolates with lower proportion of mapped read tended to has lower MIC of anti-TB drugs than those with higher proportion. These results emphasize the high applicability of WGS for determination of DR-TB and the association of particular mutations with MIC levels.

Entities:  

Year:  2020        PMID: 33382836      PMCID: PMC7775048          DOI: 10.1371/journal.pone.0244829

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  37 in total

Review 1.  The ins and outs of Mycobacterium tuberculosis drug susceptibility testing.

Authors:  E C Böttger
Journal:  Clin Microbiol Infect       Date:  2011-06-01       Impact factor: 8.067

Review 2.  Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy.

Authors:  Caroline M Pule; Samantha L Sampson; Robin M Warren; Philippa A Black; Paul D van Helden; Tommie C Victor; Gail E Louw
Journal:  J Antimicrob Chemother       Date:  2015-10-15       Impact factor: 5.790

3.  Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study.

Authors:  E Cambau; M Viveiros; D Machado; L Raskine; C Ritter; E Tortoli; V Matthys; S Hoffner; E Richter; M L Perez Del Molino; D M Cirillo; D van Soolingen; E C Böttger
Journal:  J Antimicrob Chemother       Date:  2014-11-11       Impact factor: 5.790

Review 4.  Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.

Authors:  T Schön; P Miotto; C U Köser; M Viveiros; E Böttger; E Cambau
Journal:  Clin Microbiol Infect       Date:  2016-11-01       Impact factor: 8.067

Review 5.  The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Borna Müller; Sonia Borrell; Graham Rose; Sebastien Gagneux
Journal:  Trends Genet       Date:  2012-12-13       Impact factor: 11.639

6.  Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.

Authors:  Jirarut Jonmalung; Therdsak Prammananan; Manoon Leechawengwongs; Angkana Chaiprasert
Journal:  BMC Microbiol       Date:  2010-08-20       Impact factor: 3.605

7.  Nonmutational compensation of the fitness cost of antibiotic resistance in mycobacteria by overexpression of tlyA rRNA methylase.

Authors:  Pietro Freihofer; Rashid Akbergenov; Youjin Teo; Reda Juskeviciene; Dan I Andersson; Erik C Böttger
Journal:  RNA       Date:  2016-10-03       Impact factor: 4.942

8.  What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Authors:  Jan Heyckendorf; Sönke Andres; Claudio U Köser; Ioana D Olaru; Thomas Schön; Erik Sturegård; Patrick Beckert; Viola Schleusener; Thomas A Kohl; Doris Hillemann; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Stefan Niemann; Christoph Lange; Matthias Merker
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

9.  Whole-Genome Sequencing for Drug Resistance Profile Prediction in Mycobacterium tuberculosis.

Authors:  Sebastian M Gygli; Peter M Keller; Matthias Egger; Sebastien Gagneux; Erik C Böttger; Marie Ballif; Nicolas Blöchliger; Rico Hömke; Miriam Reinhard; Chloé Loiseau; Claudia Ritter; Peter Sander; Sonia Borrell; Jimena Collantes Loo; Anchalee Avihingsanon; Joachim Gnokoro; Marcel Yotebieng
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

10.  Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations.

Authors:  L Rigouts; P Miotto; M Schats; P Lempens; A M Cabibbe; S Galbiati; V Lampasona; P de Rijk; D M Cirillo; B C de Jong
Journal:  Sci Rep       Date:  2019-08-13       Impact factor: 4.379

View more
  8 in total

1.  In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis.

Authors:  Alice Brankin; Marva Seifert; Sophia B Georghiou; Timothy M Walker; Swapna Uplekar; Anita Suresh; Rebecca E Colman
Journal:  Sci Rep       Date:  2022-10-22       Impact factor: 4.996

2.  Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment.

Authors: 
Journal:  Eur Respir J       Date:  2022-04-14       Impact factor: 33.795

3.  Use of Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Complex Drug Resistance from Early Positive Liquid Cultures.

Authors:  Xiaocui Wu; Guangkun Tan; Wei Sha; Haican Liu; Jinghui Yang; Yinjuan Guo; Xin Shen; Zheyuan Wu; Hongbo Shen; Fangyou Yu
Journal:  Microbiol Spectr       Date:  2022-03-21

Review 4.  Towards Equitable Access to Public Health Pathogen Genomics in the Western Pacific.

Authors:  Chantel Lin; Endang da Silva; Aalisha Sahukhan; Theresa Palou; Eka Buadromo; Tuyet Hoang; Benjamin P Howden
Journal:  Lancet Reg Health West Pac       Date:  2021-11-24

5.  Decreased Methylenetetrahydrofolate Reductase Activity Leads to Increased Sensitivity to para-Aminosalicylic Acid in Mycobacterium tuberculosis.

Authors:  Ji-Fang Yu; Jin-Tian Xu; Shan-Shan Yang; Mei-Na Gao; Hao-Rui Si; Dong-Yan Xiong; Jing Gu; Zhi-Long Wu; Jie Zhou; Jiao-Yu Deng
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.191

6.  Detection of Minority Variants and Mixed Infections in Mycobacterium tuberculosis by Direct Whole-Genome Sequencing on Noncultured Specimens Using a Specific-DNA Capture Strategy.

Authors:  Nuria Lozano; Val F Lanza; Julia Suárez-González; Marta Herranz; Pedro J Sola-Campoy; Cristina Rodríguez-Grande; Sergio Buenestado-Serrano; María Jesús Ruiz-Serrano; Griselda Tudó; Fernando Alcaide; Patricia Muñoz; Darío García de Viedma; Laura Pérez-Lago
Journal:  mSphere       Date:  2021-12-15       Impact factor: 4.389

7.  Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients.

Authors:  Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2021-07-26       Impact factor: 5.191

Review 8.  The Neglected Contribution of Streptomycin to the Tuberculosis Drug Resistance Problem.

Authors:  Deisy M G C Rocha; Miguel Viveiros; Margarida Saraiva; Nuno S Osório
Journal:  Genes (Basel)       Date:  2021-12-17       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.